Vuong Trieu, CHAIRMAN AND CEO, 10% Owner at Oncotelic Therapeutics, Inc. (OTLC), bought 335,759 shares at $0.04 ($15K) on 2026-06-17, disclosed to the SEC on 2026-06-17.
Chairman and CEO Vuong Trieu purchased 239,759 shares for $10,693, marking the largest insider purchase in the company's history and signaling strong conviction in the stock's potential. This significant buyback by the CEO, who owns over 10% of the company, suggests the executive believes the current valuation is undervalued.
The stock is trading at a price-to-earnings ratio of 0.07, significantly below the industry average, and has a short interest of 2.5% of the float. The stock is currently trading at $0.04 per share, with a beta of -0.211 indicating low volatility.
Insider cluster: The trade is flagged as the 'largest ever' insider purchase in the company's history, indicating a major vote of confidence from the CEO. Sector momentum: The industry has seen a 9.18% net buyer flow over the last 90 days, suggesting broader institutional support for biotech stocks.
Valuation risk: The stock has a negative beta (-0.211), which implies it may underperform during market rallies. Liquidity risk: The company has a market cap of $17.74 million, which may limit trading volume and increase volatility.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.04 | 96,000 | $4K | 28.8% |
| 2 | $0.04 | 239,759 | $11K | 71.2% |
| Total | $0.04 avg | 335,759 | $15K | 100% |
| Filing → |
| OTLC | BUY | 2025-07-10 | $2K | — | Filing → |
| OTLC | BUY | 2025-01-31 | $10K | — | Filing → |
| OTLC | BUY | 2024-11-26 | $9K | — | Filing → |